Has Edward Mannina, MD received payments from drug or device companies?

Yes. Drug and device makers reported $336 in general payments to Edward Mannina, MD across 11 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Edward Mannina, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Edward Mannina, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Edward Mannina, MD

Radiation Oncology · Slidell, LANPI 1477846913

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 11 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Teleflex LLC at 43.0% of the total. Reporting peaked in 2024 at $204 and has fallen 61.1% since, to $80 in 2025. That places this record below the midpoint for radiation oncology clinicians in LA, where the typical reported total is $527.

$336in general payments, 2019–2025

Across 11 payments — averaging $30.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teleflex LLC$144
Novocure Inc.$47
GE HealthCare$34
Novartis$23
AstraZeneca$19
Bayer$19
plus $50 from 3 others

What the payments were for

Food & beverage$336100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teleflex LLC	1	$144
Novocure Inc.	3	$47
GE HealthCare	1	$34
Novartis	1	$23
AstraZeneca	1	$19
Bayer	1	$19
Cumberland Pharmaceuticals, Inc.	1	$19
Brainlab, Inc.	1	$18
Medtronic	1	$14

How this compares

$336 in reported general payments places this provider in the 35th percentile of 58 radiation oncology providers in Louisiana.

See all radiation oncology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$793,770

Medicare patients

220

Services billed

3,910

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	47	$1,627
Tamsulosin Hcl	68	$636
Ondansetron OdtOndansetron	17	$381
Pantoprazole Sodium	14	$92

Paid to pharmacies, not to this prescriber.